Difference between revisions of "Non-small cell lung cancer, MET-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "") |
||
| Line 14: | Line 14: | ||
==Capmatinib monotherapy {{#subobject:791280|Regimen=1}}== | ==Capmatinib monotherapy {{#subobject:791280|Regimen=1}}== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
===Regimen {{#subobject:f3e479|Variant=1}}=== | ===Regimen {{#subobject:f3e479|Variant=1}}=== | ||
{| class="wikitable" style="color:white; background-color:#404040" | {| class="wikitable" style="color:white; background-color:#404040" | ||
| Line 45: | Line 42: | ||
==Tepotinib monotherapy {{#subobject:7it980|Regimen=1}}== | ==Tepotinib monotherapy {{#subobject:7it980|Regimen=1}}== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
===Regimen {{#subobject:f3eig9|Variant=1}}=== | ===Regimen {{#subobject:f3eig9|Variant=1}}=== | ||
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" | ||
Revision as of 11:40, 26 July 2022
Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Metastatic disease
Capmatinib monotherapy
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Wolf et al. 2020 (GEOMETRY mono-1) | NR | Phase 2 (RT) |
Biomarker eligibility criteria
- MET exon 14 skipping alterations
Targeted therapy
- Capmatinib (Tabrecta) 400 mg PO twice per day with or without food
Continued indefinitely
References
- GEOMETRY mono-1: Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. link to original article contains protocol PubMed NCT02414139
Tepotinib monotherapy
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Paik et al. 2020 (VISIONNSCLC) | 2016-2020 | Phase 2 (RT) |
Note: the FDA-recommended dose is 450 mg PO once per day; the dose here was the dose reported in VISION.
Biomarker eligibility criteria
- MET exon 14 skipping alterations
Targeted therapy
- Tepotinib (Tepmetko) 500 mg PO once per day
Continued indefinitely
References
- VISIONNSCLC: Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. Epub 2020 May 29. link to original article contains verified protocol PubMed NCT02864992